Telmisartan attenuates obesity-induced insulin resistance via suppression of AMPK mediated ER stress

• Published in: Biochemical and biophysical research communications 2020-03, Vol.523 (3), p.787-794
• Main Authors: Huang, Ya, Li, Yanping, Liu, Qinhui, Zhang, Jinhang, Zhang, Zijing, Wu, Tong, Tang, Qin, Huang, Cuiyuan, Li, Rui, Zhou, Jian, Zhang, Guorong, Zhao, Yingnan, Huang, Hui, He, Jinhan
• Format: Article
• Language: English
• Subjects: AMPK; ER stress; Insulin resistance; Obesity; Telmisartan
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2019.12.111

Telmisartan is a known angiotensin II (Ang II) AT1 receptor blocker (ARB). While the beneficial effect of Telmisartan on glucose and lipid metabolism has been reported, the underlying molecular mechanism remained unclear. The endoplasmic reticulum (ER) stress is considered as one of important factors contributing to insulin resistance. In this study, we found that Telmisartan alleviated diet-induced obesity and insulin resistance, suppressed inflammation in adipose tissue, and alleviated hepatic steatosis. Furthermore, we showed that Telmisartan suppressed ER stress by activating AMP-activated protein kinase (AMPK) signaling pathway in vivo. In differentiated 3T3-L1 adipocytes, Telmisartan also improved palmitate acid (PA) induced ER stress. Compound C, an AMPK inhibitor, could abolish beneficial effect of Telmisartan on ER stress. Our data indicated Telmisartan improved obesity-induced insulin resistance through suppression of ER stress by activation of AMPK. These results provided the evidence that Telmisartan may have therapeutic potential for the treatment of obesity and type II diabetes. [Display omitted] •Telmisartan alleviated diet-induced obesity and insulin resistance.•Telmisartan suppressed inflammation in adipose tissue.•Telmisartan suppressed ER stress by activating AMPK.